Publicaciones en colaboración con investigadores/as de University of Florida (13)

2024

  1. Impact of the COVID-19 Pandemic on Global TAVR Activity: The COVID-TAVI Study

    JACC: Cardiovascular Interventions, Vol. 17, Núm. 3, pp. 374-387

2022

  1. Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies

    The Lancet. Haematology, Vol. 9, Núm. 5, pp. e374-e384

2021

  1. Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 39, Núm. 7, pp. 757-767

2018

  1. A community approach to mortality prediction in sepsis via gene expression analysis

    Nature Communications, Vol. 9, Núm. 1

  2. Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies

    The Lancet Haematology, Vol. 5, Núm. 11, pp. e563-e598

2017

  1. Genetic association study of exfoliation syndrome identifies a protective rare variant at LOXL1 and five new susceptibility loci

    Nature Genetics, Vol. 49, Núm. 7, pp. 993-1004

2014

  1. International Multidisciplinary Classification of Acute Pancreatitis Severity: The 2013 Spanish Edition

    Medicina Intensiva, Vol. 38, Núm. 4, pp. 211-217

2013

  1. Einteilung des Schweregrads der akuten Pankreatitis: Internationale, multidisziplinäre klinische Klassifikation auf Basis pathogenetischer Determinanten: Deutsche Version 2013

    Zeitschrift fur Gastroenterologie, Vol. 51, Núm. 6, pp. 544-550

2012

  1. Determinant-based classification of acute pancreatitis severity: An international multidisciplinary consultation

    Annals of Surgery, Vol. 256, Núm. 6, pp. 875-880

2007

  1. 2006 Bethesda international consensus recommendations on the flow cytometric immunophenotypic analysis of hematolymphoid neoplasia: Medical indications

    Cytometry Part B - Clinical Cytometry

2001

  1. Optimal number of reagents required to evaluate hematolymphoid neoplasias: Results of an International Consensus Meeting

    Communications in Clinical Cytometry, Vol. 46, Núm. 1, pp. 23-27

2000

  1. Minimal number of reagents required to evaluate hematolymphoid neoplasias: Results of an international consensus meeting

    CYTOMETRY

1999

  1. Clinically useful information provided by the flow cytometric immunophenotyping of hematological malignancies: Current status and future directions

    Clinical Chemistry, Vol. 45, Núm. 10, pp. 1708-1717